Androgen Deprivation Therapy: Monitoring and Managing the Complications

Hematology/Oncology Clinics of North America

Volumn 20, Issue 4, 2006, Pages 909-923

  Higano, Celestia ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARNITINE; CISPLATIN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; GABAPENTIN; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROSTAGLANDIN E1; RECOMBINANT ERYTHROPOIETIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUPUNCTURE; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANXIETY; BEHAVIOR THERAPY; BONE DENSITY; CALCIUM INTAKE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE EXACERBATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; GYNECOMASTIA; HAIR DISEASE; HEART DISEASE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; LIBIDO DISORDER; MENTAL INSTABILITY; METABOLIC DISORDER; MUSCLE ATROPHY; MUSCLE MASS; NEUROPATHIC PAIN; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEX THERAPY; SIDE EFFECT; STROKE; TESTIS ATROPHY; THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; WEAKNESS; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; DISEASE MANAGEMENT; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 33746190667     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.03.013     Document Type: Review

References (78)

1. Aubin S, Higano C. The combined treatment approach for men undergoing hormonal therapy for prostate cancer. Presented at the 5th Annual Society of Urologic Oncology meeting. Bethesda, MD, December 3-4, 2004.
2. Moyad M.A. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 59 4 Suppl. 1 (2002) 20-33
3. Frodin T., Alund G., and Varenhorst E. Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 7 2 (1985) 203-208
4. Buchholz N.P., Mattarelli G., and Buchholz M.M. Post-orchiectomy hot flushes. Eur Urol 26 2 (1994) 120-122
5. Parmar H., Edwards L., Phillips R.H., et al. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 59 3 (1987) 248-254
6. Smith Jr. J.A. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J Urol 131 6 (1984) 1110-1112
7. Quella S., Loprinzi C.L., and Dose A.M. A qualitative approach to defining "hot flashes" in men. Urol Nurs 14 4 (1994) 155-158
8. Moyad M.A. Promoting general health during androgen deprivation therapy (ADT): A rapid 10-step review for your patients. Urol Oncol 23 (2005) 56-64
9. Charig C.R., and Rundle J.S. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33 3 (1989) 175-178
10. Spetz A.C., Hammar M., Lindberg B., et al. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 166 2 (2001) 517-520
11. Charig C.R., and Rundle J.S. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33 3 (1989) 175-178 [in Italian]
12. Barton D., Loprinzi C., Quella S., et al. Depomedroxyprogesterone acetate for hot flashes. J Pain Symptom Manage 24 6 (2002) 603-607
13. Langenstroer P., Kramer B., Cutting B., et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 174 2 (2005) 642-645
14. Sartor O., and Eastham J.A. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 92 4 (1999) 415-416
15. Tassinari D., Fochessati F., Panzini I., et al. Rapid progression of advanced "hormone-resistant" prostate cancer during palliative treatment with progestins for cancer cachexia. J Pain Symptom Manage 25 5 (2003) 481-484
16. Moon T.D. Cyproterone acetate for treatment of hot flashes after orchiectomy. J Urol 134 1 (1985) 155-156
17. Cervenakov I., Kopecny M., Jancar M., et al. "Hot flush," an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. Int Urol Nephrol 32 1 (2000) 77-79
18. Atala A., Amin M., and Harty J.I. Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology 39 2 (1992) 108-110
19. Gerber G.S., Zagaja G.P., Ray P.S., et al. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 55 1 (2000) 97-101
20. Updates FDA. Labeling for Ortho Evra Contraceptive Patch. Available at: http://www.fda.gov/bbs/topics/news/2005/NEW01262.html. Accessed January 1, 2006.
21. Moverare S., Skrtic S., Lindberg M.K., et al. Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-alpha and -beta in murine bone marrow/bone. Eur J Endocrinol 151 2 (2004) 259-263
22. Roth A.J., and Scher H.I. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 7 2 (1998) 129-132
23. Quella S.K., Loprinzi C.L., Sloan J., et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 162 1 (1999) 98-102
24. Guttuso Jr. T.J. Gabapentin's effects on hot flashes and hypothermia. Neurology 54 11 (2000) 2161-2163
25. Jeffery S.M., Pepe J.J., Popovich L.M., et al. Gabapentin for hot flashes in prostate cancer. Ann Pharmacother 36 3 (2002) 433-436
26. Hammar M., Frisk J., Grimas O., et al. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 161 3 (1999) 853-856 [in Italian]
27. Lonn E., Bosch J., Yusuf S., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 11 (2005) 1338-1347
28. Miller III E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 1 (2005) 37-46
29. Stone P., Hardy J., Huddart R., et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36 9 (2000) 1134-1141
30. Choo R., Chander S., Danjoux C., et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?. Can J Urol 12 1 (2005) 2547-2552
31. Pirl W.F., Siegel G.I., Goode M.J., et al. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 11 6 (2002) 518-523
32. Shahpesandy H. Different manifestation of depressive disorder in the elderly. Neuro Endocrinol Lett 26 6 (2005) 691-695
33. Fava M., Thase M.E., and DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 66 1 (2005) 85-93
34. Cathcart F. The contribution of clinical psychology to palliative medicine. In: Doyle D., Hanks G., Cherny N., et al. (Eds). The Oxford textbook of palliative medicine. 3rd edition (2004), Oxford University Press, Oxford 1073-1078
35. Moorey S., and Greer S. Cognitive behavior therapy for people with cancer (2002), Oxford, Oxford University Press
36. Bremer J. Carnitine-metabolism and functions. Physiol Rev 63 4 (1983) 1420-1480
37. Cruciani R.A., Dvorkin E., Homel P., et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci 1033 (2004) 168-176 [in Italian]
38. Graziano F., Bisonni R., Catalano V., et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 86 12 (2002) 1854-1857
39. Pistone G., Marino A., Leotta C., et al. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 20 10 (2003) 761-767
40. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 5 (2003) 1808-1811
41. Salminen E., Portin R., Korpela J., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 89 6 (2003) 971-976
42. Green H.J., Pakenham K.I., Headley B.C., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 4 (2002) 427-432
43. Jenkins V.A., Bloomfield D.J., Shilling V.M., et al. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96 1 (2005) 48-53
44. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 2 (2002) 599-603
45. Higano C.S., Ellis W., Russell K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 5 (1996) 800-804
46. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 6 (2002) 2361-2367 [discussion 7]
47. Segal R.J., Reid R.D., Courneya K.S., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21 9 (2003) 1653-1659
48. Dupler T.L., and Cortes C. Effects of a whole-body resistive training regimen in the elderly. Gerontology 39 6 (1993) 314-319
49. Treuth M.S., Ryan A.S., Pratley R.E., et al. Effects of strength training on total and regional body composition in older men. J Appl Physiol 77 2 (1994) 614-620 [in Italian]
50. Fiatarone M.A., O'Neill E.F., Ryan N.D., et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 330 25 (1994) 1769-1775
51. Pyka G., Lindenberger E., Charette S., et al. Muscle strength and fiber adaptations to a year-long resistance training program in elderly men and women. J Gerontol 49 1 (1994) M22-M27
52. McCartney N., Hicks A.L., Martin J., et al. Long-term resistance training in the elderly: effects on dynamic strength, exercise capacity, muscle, and bone. J Gerontol A Biol Sci Med Sci 50 2 (1995) B97-B104
53. Ades P.A., Ballor D.L., Ashikaga T., et al. Weight training improves walking endurance in healthy elderly persons. Ann Intern Med 124 6 (1996) 568-572
54. Rejeski W.J., Brawley L.R., and Shumaker S.A. Physical activity and health-related quality of life. Exerc Sport Sci Rev 24 (1996) 71-108 [in Swedish]
55. Martin J.E., Dubbert P.M., and Cushman W.C. Controlled trial of aerobic exercise in hypertension. Circulation 81 5 (1990) 1560-1567
56. Hurley B.F., Hagberg J.M., Goldberg A.P., et al. Resistive training can reduce coronary risk factors without altering VO2max or percent body fat. Med Sci Sports Exerc 20 2 (1988) 150-154 [in Swedish]
57. Castaneda C., Layne J.E., Munoz-Orians L., et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 25 12 (2002) 2335-2341
58. Alfthan O., and Holsti L.R. Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma. Scand J Urol Nephrol 3 3 (1969) 183-187
59. Waterfall N.B., and Glaser M.G. A study of the effects of radiation on prevention of gynaecomastia due to oestrogen therapy. Clin Oncol 5 3 (1979) 257-260
60. Tyrrell C.J., Payne H., Tammela T.L., et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 60 2 (2004) 476-483 [in Italian]
61. Montorsi F., Guazzoni G., Strambi L.F., et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 158 4 (1997) 1408-1410
62. Padma-Nathan H., McCullough A., Giuliano F., et al. Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J Urol 169 (2003) 1402
63. Navon L., and Morag A. Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties. Qual Health Res 13 10 (2003) 1378-1392
64. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 2 (2005) 154-164
65. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 31 (2005) 7897-7903
66. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 103 2A (1997) 12S-17S [discussion 7S-9S]
67. Krupski T.L., Smith M.R., Lee W.C., et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101 3 (2004) 541-549
68. Higano C., Shields A., Wood N., et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64 6 (2004) 1182-1186
69. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 13 (2001) 948-955
70. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 6 (2003) 2008-2012
71. Smith M.R., McGovern F.J., Fallon M.A., et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91 12 (2001) 2238-2245
72. Strum S.B., McDermed J.E., Scholz M.C., et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 6 (1997) 933-941
73. Beshara S., Letocha H., Linde T., et al. Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Prostate 31 3 (1997) 153-160
74. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 12 (1988) 1595-1607
75. Nishiyama T., Ishizaki F., Anraku T., et al. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90 2 (2005) 657-660
76. Arrer E., Jungwirth A., Mack D., et al. Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]. J Clin Endocrinol Metab 81 7 (1996) 2508-2511
77. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 9 (2001) 4261-4267 [in Italian]
78. Inaba M., Otani Y., Nishimura K., et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 54 1 (2005) 55-59